UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Serum phosphatidylcholine is lower among breast cancer patients on systemic chemotherapy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12571-e12571

2017

Volltextzugriff (PDF)

Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study

Gynecologic oncology, 2008-03, Vol.108 (3), p.500-504

2008

Volltextzugriff (PDF)

Interplay between B cell and GABA metabolism (GABAm) and association with immune evasion in breast carcinoma (BC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1097-1097

2022

Volltextzugriff (PDF)

Is there a role for 21-gene recurrence score in mucinous carcinoma of breast?

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12538-e12538

2018

Volltextzugriff (PDF)

Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12508-e12508

2019

Volltextzugriff (PDF)

Comprehensive characterization of androgen receptor expression in breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1035-1035

2023

Volltextzugriff (PDF)

Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1112-TPS1112

2022

Volltextzugriff (PDF)

Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1052-1052

2020

Volltextzugriff (PDF)

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1038-1038

2021

Volltextzugriff (PDF)

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1034-1034

2021

Volltextzugriff (PDF)

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

The lancet oncology, 2008-02, Vol.9 (2), p.117-123

2008

Volltextzugriff (PDF)

Review of next generation sequencing outcomes in patients with metastatic breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12558-e12558

2017

Volltextzugriff (PDF)

Emerging treatments for ovarian cancer

Expert opinion on emerging drugs, 2003-05, Vol.8 (1), p.203-216

2003

Volltextzugriff (PDF)

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1041-1041

2019

Volltextzugriff (PDF)

Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1055-1055

2020

Volltextzugriff (PDF)

Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1040-1040

2018

Volltextzugriff (PDF)

Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12554-e12554

2017

Volltextzugriff (PDF)

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1056-1056

2018

Volltextzugriff (PDF)

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy

Hematology/oncology clinics of North America, 2003-08, Vol.17 (4), p.969-975

2003

Volltextzugriff (PDF)

Phosphorylated and dephosphorylated linker histone H1 reside in distinct chromatin domains in Tetrahymena macronuclei

Molecular biology of the cell, 1995-08, Vol.6 (8), p.1077-1087

1995

Volltextzugriff (PDF)

Generation and characterization of novel antibodies highly selective for phosphorylated linked histone H1 in Tetrahymena and HeLa cells

Chromosoma, 1994-04, Vol.103 (2), p.111-121

1994

Volltextzugriff (PDF)

Generation and characterization of novel antibodies highly selective for phosphorylated linker histone H1 in Tetrahymena and HeLa cells

Chromosoma, 1994-04, Vol.103 (2), p.111-121

1994

Volltextzugriff (PDF)

The Differential Regulation of Insulin-like Growth Factor (IGF) inding Proteins by IGF-I During the Life Span of the Rat

Journal of gerontology (Kirkwood), 1994-09, Vol.49 (5), p.215

1994

Volltextzugriff (PDF)

Palbociclib and Letrozole in Advanced Breast Cancer

The New England journal of medicine, 2016-11, Vol.375 (20), p.1925-1936

2016

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(184)
Mit Volltextzugriff
(164)

Publikationsform

Sprache

Englisch
(193)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(90)
Humans
(80)
Female
(46)
Oncology
(29)
Adult
(25)
Animals
(25)
Middle Aged
(25)
Male
(23)
Biological And Medical Sciences
(22)
Aged
(15)
Breast Cancer
(14)
General & Internal Medicine
(13)
Medical Sciences
(13)
Multidisciplinary Sciences
(13)
Science & Technology - Other Topics
(13)
Mice
(12)
Biochemistry & Molecular Biology
(11)
Fundamental And Applied Biological Sciences. Psychology
(11)
Breast Neoplasms - Drug Therapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Serum phosphatidylcholine is lower among breast cancer patients on systemic chemotherapy

Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study

Interplay between B cell and GABA metabolism (GABAm) and association with immune evasion in breast carcinoma (BC)

Is there a role for 21-gene recurrence score in mucinous carcinoma of breast?

Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer

Comprehensive characterization of androgen receptor expression in breast cancer

Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC)

Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC)

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

Review of next generation sequencing outcomes in patients with metastatic breast cancer

Emerging treatments for ovarian cancer

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC)

Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC)

Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009)

Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy

Phosphorylated and dephosphorylated linker histone H1 reside in distinct chromatin domains in Tetrahymena macronuclei

Generation and characterization of novel antibodies highly selective for phosphorylated linked histone H1 in Tetrahymena and HeLa cells

Generation and characterization of novel antibodies highly selective for phosphorylated linker histone H1 in Tetrahymena and HeLa cells

The Differential Regulation of Insulin-like Growth Factor (IGF) inding Proteins by IGF-I During the Life Span of the Rat

Palbociclib and Letrozole in Advanced Breast Cancer

Suchergebnisse filtern